Peptide-major histocompatibility complex class I derived from Tyrosinase, MART-1, and MAGE-A6 (pMHC-I (TYR/MART-1/MAGE-A6))

The Peptide-major histocompatibility complex class I (pMHC-I) derived from Tyrosinase, MART-1, and MAGE-A6 represents a composite therapeutic target used primarily in melanoma immunotherapy. These complexes are formed when dendritic cells (DCs) process melanoma-associated antigens and present the resulting peptides on their surface via MHC class I molecules, typically HLA-A*02:01 (PubMed: 10449301). Tyrosinase and MART-1 (Melan-A) are melanocyte differentiation antigens, while MAGE-A6 is a cancer-testis antigen; all three are frequently overexpressed in malignant melanoma. The primary biological function of these complexes is to serve as a signal for the activation and expansion of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs). When targeted by dendritic cell vaccines or TCR-engineered T-cells, these pMHC complexes facilitate the recognition and lysis of tumor cells (Nature Reviews Immunology). A significant therapeutic challenge is the potential for on-target, off-tumor toxicity, such as autoimmune vitiligo, because Tyrosinase and MART-1 are also expressed in normal melanocytes (Journal of Clinical Oncology). This multi-antigen approach is specifically designed to minimize the risk of tumor immune escape through antigen loss or heterogeneity.

Other names

Melanoma-associated antigen pMHC complexesTyrosinase/MART-1/MAGE-A6 peptide-HLA complexesDendritic cell-presented melanoma antigenspMHC-I (Tyrosinase/MART-1/MAGE-A6)

Presentation of tumor-associated antigen peptides to CD8+ cytotoxic T lymphocytes (CTLs) via MHC class I molecules to induce a specific anti-tumor cellular immune response.